MedTrace Logo

Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

NCT06730308 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-12-12

No results posted yet for this study

Summary

This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.

Conditions

  • Thymoma

Interventions

RADIATION

Radiotherapy

Hypofractionated radiotherapy

DRUG

Concurrent chemotherapy

weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)

DRUG

Methylprednisolone

Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-20
Primary Completion
2028-11-19
Completion
2028-11-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06730308 on ClinicalTrials.gov